ODAIA, a Scale Up 7th Cohort member, helps pharmaceutical companies better understand and connect with doctors and healthcare professionals by making sense of complex data. Imagine a tool that takes all the information a company has about doctors' needs and behavior, and turns it into easy-to-follow insights. ODAIA’s platform, called MAPTUAL, uses artificial intelligence to do just that, helping companies figure out which doctors to talk to, what they need, and how best to communicate with them.

The platform analyzes data from many different sources, including how doctors make decisions about their patients, and then provides recommendations for how pharmaceutical teams can reach out effectively. This means that instead of spending time sorting through loads of data, pharma teams can focus on building stronger relationships with the right doctors.

With ODAIA’s help, life sciences companies can make their communication more personalized and efficient, ensuring they provide the right information to doctors at the right time, ultimately improving healthcare decisions and patient care.

ODAIA has gathered a list of customers that include the world’s largest pharma companies, including Janssen, Novo Nordisk, and AstraZeneca. Additionally, ODAIA closed a $25 million series B financing co-led by Threshold Ventures and Monograph Capital to help expand its presence both in North America and beyond. 

Odaia in Three:

What problem is ODAIA solving? ODAIA is solving the problem of complex data navigation for pharmaceutical teams, enabling them to connect more effectively with healthcare professionals.

What’s innovative about ODAIA? ODAIA integrates data science, behavioral science, and AI in its MAPTUAL platform to deliver deep insights into healthcare professionals and patient decision-making, transforming commercial strategies for life sciences firms.

Who can use ODAIA? Pharmaceutical teams and life sciences companies can use ODAIA’s solutions to enhance their engagement strategies with healthcare professionals.